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Japanese encephalitis (JE) is one of the most dreaded 
mosquito-borne viral encephalitis known to afflict 
humans. The Japanese encephalitis virus (JEV) is a 
neurotropic flavivirus that affects the CNS, causing 
extensive damage that may lead to fatality in about 
one third of patients. Half of the survivors suffer from 
severe neuropshychiatric sequelae. With nearly 3 bil-
lion people living under the current JE-endemic  
region, recurring incidents of epidemic are being  
reported at regular intervals. With no established  
antiviral therapies against JE available, vaccination 
has been the only way of preventing JE. Two types of 
JE vaccines are currently in vogue although the safety 
of administering them is questionable, in certain indi-
viduals. Thus, there is a need to develop a safe, af-
fordable and potent JE vaccine and this review 
addresses the current efforts in this direction. This  
review also focuses on the pathophysiology of JE and 
efforts towards a possible breakthrough in anti-JEV 
therapy. 
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Origin and spread of JEV 
FROM the 1870s, recurring epidemics of encephalitis  
have been reported from the islands of Japan, especially 
during the summer season, with major outbreaks occurring 
every 10 years. This summer encephalitis was termed as 
type B encephalitis, to differentiate from von Economo’s 
encephalitis lethargica. The name type B was later 
dropped and in 1935 the Nakayama strain of Japanese  
encephalitis virus (JEV) was isolated from the brain of a 
fatal case1. The virus was later classified as a member of 
the genus Flavivirus (family Flaviviridae) named after 
the prototype Yellow fever virus (Latin; flavi = yellow). 
The genus consists of over 70 other closely related virus 
species. The origins of JEV are uncertain, but phylo-
genetic comparisons with other flaviviruses suggest that 
it evolved from an African ancestral virus, perhaps as  
recently as a few centuries ago2 and evolved into its pre-
sent form in the Indonesia–Malaysia region3. Since then, 
the virus has spread in South Asia, Southeast Asia, East 
Asia and the Pacific regions4. Rapid globalization, popu-
lation explosion, changes in global climatic condition,  
industrialization and deforestation, all seem to correlate 
with the spread of the virus into newer territories. Today, 
with approximately three billion people living in the JE-
endemic region, there are estimated 35,000–50,000 cases 
and 10,000–15,000 deaths annually, thereby making JE 
one of the most dreaded vector-borne viral encephalitis in 
the world5 (Figure 1). 
 In India, JE as a disease was first reported in 1955 
when clinical cases were detected in Vellore and Pondi-
cherry in southern India. The virus was however, not  
recovered from humans until 1958, when three isolations 
were made from the brain tissue of infected persons. Un-
til early 1970s, the disease was reported only from south-
ern India with periodic focal reports of its occurrence. A 
major outbreak resulting in 42.6% case-fatality rate was 
reported from Bankura district of West Bengal in 1973. 
Subsequently, the disease spread to other states and 
caused a series of outbreaks in different parts of the coun-
try. In 1978, cases were reported from 21 states and union 
territories, and from then onwards till 2007 there have 
been 103,389 reported cases of JE in India that has led to 
33,729 deaths6. Approximately 597,542,000 people in  
India live under the JE-endemic regions and there are 
1500–4000 reported cases every year7. These figures are 
based on total reported cases and it is quite possible that 
several cases may go unreported and hence the actual 
magnitude of the threat of JE may be considerably higher 
both in the Indian as well as the global context. 
Enzootic cycle of JEV 
JE is a vector-borne viral disease. JEV is transmitted  
between vertebrate hosts by mosquitoes belonging to the 
Culex sp. (Figure 2). The virus is able to replicate within 
the salivary glands of the mosquitoes. Mature JE virions 
remain entrapped in intracellular vacuoles and are later 
released into the apical cavity of salivary gland cells 
through the fusion of these vacuoles with the apical 
plasma membrane. This process is associated with pri-
mary re-synthesis of saliva in mosquitoes following 
blood feeding activity. Another type of shedding involves 
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Figure 1. Japanese encephalitis (JE) endemic regions. The current JE-endemic region consisting of entire Southeast Asia, parts 
of Russia and Australia. The possible direction of spread of the disease is shown as broken arrows. (Figure not to scale; adapted 
from Ghosh and Basu, PLoS Neglected Tropical Diseases, 2009.)  
 
 
 
Figure 2. Enzootic transmission cycle of JE virus. The virus is transmitted to vertebrate hosts by mosquitoes belonging to the 
Culex sp. Pigs serve as amplification hosts and forms a critical link in the transmission cycle. Ardeid water birds and bats serve as 
virus reservoirs. Humans are dead end hosts as the virus cannot be transmitted from an infected person to another. 
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virus particles, either singly or in mass, being released  
directly through the apical plasma membrane8. Compo-
nents of the mosquito saliva may also modulate infection 
by altering the local cytokine milieu. Feeding by mosqui-
toes of Culex sp. or administration of sialokinin-I, a mos-
quito salivary protein, have been found to downregulate 
IFN-γ production and upregulate the TH2 cytokines, IL-4 
and IL-10 (ref. 9). 
 Human infections are mainly spread by Culex tri-
taeniorrhynchus which breeds in pools of stagnant water 
such as rice paddy fields10. Because the rice paddy is un-
avoidable, majority of the population in rural Asia has 
been infected with the virus by early adulthood11. Wading 
ardeid water birds (e.g. herons and pond egrets) and bats 
serve as virus reservoirs or maintenance hosts, but the  
virus regularly spills over into pigs, members of the  
family of Equidae (e.g. horses and donkeys) and humans. 
Pigs are considered as the main amplifications hosts as 
viraemia results with a high titre. Due to the close pro-
ximity of pigs with human dwellings these animals are 
considered main component in the transmission cycle 
with respect to human infection12. JEV infection in other 
domestic animals does not result in high viraemia and 
thus, they are not expected to transmit the virus to humans.  
Molecular architecture of JEV 
The JE virion consists of a single strand of positive-sense 
RNA of around 11 kilobase, inside a nucleocapsid and is 
surrounded by a glycoprotein-containing envelope. The 
RNA comprises a short 5′ untranslated region (UTR), a 
longer 3′UTR and a single open reading frame between 
them. It codes for a single polyprotein, which is transla-
tionally and post-translationally cleaved by viral and host 
proteases into three structural proteins (core-C, pre-
membrane-PrM and envelope-E), and seven nonstructural 
(NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
and NS5). The C protein (12–14 kDa) is highly basic and 
combines with the RNA to form the nucleocapsid13. The 
prM is closely associated with the E protein, forming a 
heterodimer and is thought to act as a ‘chaperone’ to it, 
impairing its function until after virion release. Immedi-
ately prior to virion release, the prM protein (18–19 kDa) 
is cleaved to its mature M protein (8–9 kDa) form. This 
allows the formation of E protein homodimers, which are 
thus ‘activated’. The prM protein of JEV contains a single 
N-linked glycosylation site, which is highly conserved 
among the JEV strains. Researches indicated that this 
highly conserved N glycosylation motif in prM is crucial 
for multiple stages of JEV biology: prM biogenesis, virus 
release and pathogenesis14. The E protein is the largest 
structural protein (53–55 kDa), with up to two potential 
gylcosylation sites. It is the major target for the humoral 
immune response and is thought to be important for viral 
entry into host cells. It is worth mentioning that low pH is 
extremely important for viral entry into the cell to trigger 
viral membrane fusion with host endosomal membrane, 
thereby releasing the nucleoplasmid in the cytosol. 
Pathophysiology and clinical manifestations of JE 
The course of JEV infection, starting from its entry till 
reaching its site of action, the central nervous system 
(CNS), is not well-defined. Studies with other flavi-
viruses have led to the belief that upon entry through 
mosquito bite, the virus infects Langerhan’s dendritic 
cells in the skin15 and is carried to nearest draining lymph 
nodes16, thereby initiating a round of early immune res-
ponse. Unfortunately for the host, this is not sufficient to 
counter the virus and it spreads to secondary lymphoid 
organs before entering the blood circulation through the 
efferent lymphatic system. During the ensuing transient 
viraemia, peripheral organs such as kidney, liver and 
spleen are known to be infected17, after which the neuro-
tropic flavivirus spreads to the CNS. How JEV manages 
to evade the host’s peripheral immune response is another 
matter of speculation, as there are no definitive studies 
regarding this aspect, till date. Once the virus evades the 
immune system, it crosses the blood–brain barrier (BBB) 
to enter the CNS. JEV may cross the BBB by passive 
transport across the endothelium, by active replication  
in endothelial cells, or by a ‘Trojan horse’ mechanism in 
which the virus is carried into the brain by infected  
inflammatory cells18. Monocytes and macrophages are 
thought to be probable carriers of the virus into the CNS 
as studies have shown that the virus can survive for a  
prolonged time and effectively replicate within these 
cells19,20. The structural and functional integrity of the 
BBB is critically compromised during JE21 which may 
possibly be caused by matrix metalloproteases released in 
the infected brain22. Due to the impaired functioning of 
the BBB, peripheral inflammatory cells are recruited to 
the infected brain at later stages of JE that exacerbates the 
damage.  
 JEV causes extensive neuronal damage in the brain, 
though in many cases, the virus is probably not directly 
involved in the destruction of brain tissue but may cause 
damage indirectly by triggering cell-mediated immune 
response by activating microglia. Microglias are the resi-
dent immune cells of the CNS and have a critical role in 
host defense against invading microorganisms. Microglial 
activation is viewed as an adaptive response whereby  
microglia release neuroprotective factors to facilitate the 
recovery of injured neurons and they also phagocytose 
dying or damaged neurons, before they lyse and release 
toxic agents into surrounding areas. JEV infection has 
been shown to activate microglia both morphologically 
and functionally, in vivo, that leads to an elevation of pro-
inflammatory mediators, such as IL-6, TNF-α, RANTES 
and MCP-1. These proinflammatory mediators and cyto-
toxins released from activated microglia are instrumental 
in inducing neuronal death that accompanies JE23.  
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Neuronal death by secreted TNF is mediated by the TNF  
receptor-associated death domain protein (TRADD)24, 
which there upon regulates a downstream apoptotic cas-
cade in neurons. However, neuronal death also activates 
microglia and astrocytes and thus, the inflammatory cycle 
goes on. Nitric oxide (NO) also plays an important role in 
inflammation during JE infection, although NO itself is a 
strong antimicrobial agent researchers have shown that it 
profoundly inhibits viral RNA synthesis, viral protein  
accumulation and virus release from infected cells25. 
Thus, NO may play a crucial role in the innate immunity 
of the host and its ability to restrict the initial stages of 
JEV infection in the CNS. 
 Besides neuronal and microgial cells, studies have 
shown that astrocytes are also infected by JEV26. Astro-
cytes are known to maintain homeostasis in the CNS and 
to support the survival and information processing func-
tions of neurons. They respond promptly to CNS infection 
and help regulate neuroinflammation27. JEV infection re-
sults in astrocyte activation, but the infection overwhelms 
the capacity of even activated astrocytes to maintain meta-
bolic homeostasis, resulting in an over accumulation of 
toxic byproducts of metabolism that are detrimental to neu-
ronal viability. Though JEV infection triggers metabolic 
reprogramming by upregulating the expression of several 
proteins such as IP-10 (ref. 28), ceruloplasmin and 
glutamine synthetase, involved in the metabolic pathways 
crucial for maintaining neuronal health, this increase is 
insufficient to meet the increased demand that accompa-
nies JEV infection29. Astrocytes, being a component of 
the BBB, may also help in the transmission of JEV from 
peripheral tissues to the cerebrospinal fluid. JEV also 
causes the upregulation of certain host genes in the brain. 
An in vivo study using subtraction hybridization technique 
has identified several genes whose expression is upregu-
lated by JEV in mouse brain30,31. It has been further  
demonstrated that several of these genes are also induced 
in the CNS by rabies virus and Sindbis virus. Thus, it  
appears that different neurotropic viruses activate com-
mon host cell pathways during infection of CNS30,31. 
 JE typically develops in patients after an incubation  
period of 5–15 days32. In humans, most JEV infections 
are asymptomatic, with about one in 300 JEV infections 
resulting in symptoms ranging from non-specific febrile 
illness to severe meningoencephalitis, characterized by 
fever, reduced consciousness, seizures and focal neuro-
logical signs33. At later stages, poliomyelitis-like flaccid 
paralysis and parkinsonian syndrome develops, which 
manifests the classic description of JE – dull, flat, mask-
like face with wide, unblinking eyes, tremor, generalized 
hypertonia, cogwheel rigidity, and other abnormalities in 
movement34. Histopathological and imaging studies have 
shown JEV infection and inflammation in the anterior 
horn cells of the spinal cord, which provided an anatomical 
correlate for these presentations35. Radiological studies 
also support the earlier observations from pathological 
investigations implicating the basal ganglia, especially 
the substantia nigra and thalamus in the parkinsonian 
syndromes seen in JE, which include tremor, cogwheel 
rigidity and mask-like faces36. Recently, there has  
been further molecular evidence of the involvement of  
nigrostriatal pathway in JE survivors with movement 
complications. In the study, (99m) Tc-TRODAT-1 and 
(123)I-IBZM SPECT imaging revealed that presynaptic 
dopaminergic neurons in JE patients are more susceptible 
to JEV than post-synaptic striatal neurons37. Electroen-
cephalographic abnormalities observed in JE patients  
include the presence of alpha, theta and delta coma, and 
epileptiform conditions38. Symptoms of brainstem infec-
tion include changes in the respiratory pattern, flexor and 
extensor posturing, and abnormalities in the papillary and 
occulocephalic reflexes39. In fatal cases of JE, patho-
logical changes are polymorphic and diffuse, involving 
various parts of the nervous system where the brain 
shows a severe degree of vascular congestion, microglial 
proliferation and formation of gliomesenchymal nodules, 
focal or confluent areas of cystic necrosis, cerebral  
oedema and transcompartmental shift40. Many survivors 
of JE acquire neuropsychiatric sequelae with cognitive 
and language impairment, in which case the disease pre-
sents itself not only as a killer but also as a cause of an  
immense social and financial burden, especially for a  
developing country33. Recently, it has been reported that 
neural progenitor cells (NPC) are permissive to JEV  
infection both in vivo and in vitro, which leads to their 
growth retardation. The pathophysiological relevance of 
these observations was supported by profound decrement 
in actively proliferating NPCs in the subventricular zone 
(SVZ) of JEV-infected animals. Infection of the NPCs 
and suppression of their proliferation might be primarily 
responsible for dysregulated neurogenesis and develop-
ment of cognitive deficits in survivors of JE41.  
Prophylactic strategies against JE  
Due to lack of definitive therapeutic countermeasures to 
combat JE, implementation of prophylactic strategies  
remains the best way to prevent JE. The most important 
aspect of the prevention of JE spread is vector control. 
Paddy fields not only provide an ideal breeding ground 
for mosquitoes but also attract migratory birds, thereby 
helping the spread of the virus. Responsible use of larvi-
cides, insecticides, and adopting ecofriendly methods 
such as using neem cakes and growing larvivorous fish 
are useful in controlling mosquitoes in paddy fields4. As 
pigs are the amplification host in the transmission cycle 
of the virus, close monitoring of domesticated animals is 
necessary. Vaccinating pigs is also a logical way to  
acquire protection against JEV by breaking the mosquito–
pig–human transmission cycle42.  
 Human vaccination remains, till date, the most effec-
tive measure to prevent JE. Multiple vaccines exist to 
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control JE, but all have limitations. Unfortunately, unlike 
smallpox, it is difficult to eradicate JEV by vaccination, 
because human beings are actually a dead-end host of the 
virus. The formalin-inactivated vaccine against JEV was 
produced from infected mouse brain-derived tissue soon 
after the virus was discovered. This type of vaccine, 
manufactured by the Research Foundation for Microbial 
Diseases of Osaka University, Japan, became commer-
cially available in Japan (as the Japanese Biken vaccine 
JE-VAX) and was produced in Korea by the Green Cross 
Vaccine company. These were later licensed to be pro-
duced in the United States also43. This is the only JE  
vaccine recommended by the World Health Organization 
(WHO), but there have been several concerns with its 
side effects44. These vaccines are expensive and require 
multiple doses to maintain efficacy and immunity. The 
Biken vaccine is no longer produced. The Korean Green 
Cross vaccine needs to be administered also in three 
doses on day 0, 7 and 28 after birth, with boosters given 
every 12 months following primary course, then every 
three years, unless at particular risk in which case annual 
boosters are recommended. This makes its use difficult 
for people in developing countries. Researchers have 
been trying to avoid a multidose requirement of the vaccine 
by using adjuvants such as biodegradable poly (gamma-
glutamic acid) nanoparticles and alum45. Another mouse 
brain inactivated JE vaccine was produced in India by the 
Central Research Institute (CRI) in Kasauli46 but the pro-
duction of the vaccine was suspended from 2007 as the 
institute had failed to upgrade its main laboratory accord-
ing to the GMP norms of WHO47. An inexpensive, live 
attenuated vaccine (SA14-14-2)48 was licensed by China 
in 1988, but WHO does not approve it for human use be-
cause it is produced in primary hamster kidney cells. Ini-
tially, this vaccine was used almost exclusively in China 
and parts of Korea, but it is now being widely used in the 
Indian subcontinent as well as Nepal. The vaccine seems 
to be highly effective, and very few adverse effects have 
been observed following its use in Nepal49. No informa-
tion is, however, available on the efficacy and side effects 
of this vaccine in India. Neuroattenuation of the virulent 
JE SA14-14-2 strain is reported to be based on 57 nucleo-
tide changes and 24 amino acid substitutions, suggesting 
that reversion to neurovirulence of the vaccine strain is 
unlikely. Though the vaccine was adjudged to be safe and 
efficacious by the WHO’s Global Advisory Committee 
on Vaccine Safety, several parameters such as safety in 
immunocompromised individuals and pregnant women, 
viral shedding in vaccines and implications of the shed-
ding, efficacy in infants less than one year of age, re-
mains to be ascertained50. The recently developed Vero 
cell-derived inactivated JE vaccine containing the puri-
fied, inactivated JEV strain SA14-14-2 with aluminum 
hydroxide as adjuvant seems to be a promising candidate 
and has passed the phase III randomized controlled 
trial51. Technology for a Vero cell-derived vaccine based 
on an Indian strain of JEV52 has been developed and the 
vaccine is under pre-clinical development. 
 Several efforts have been and are still being made to 
develop recombinant vaccines for JEV. A highly attenu-
ated recombinant vaccinia virus, NYVAC53 was used for 
JE vaccine development which proved to be quite success-
ful54. Other strains tested include modified vaccinia virus 
Ankara strain55,56. Later studies focused on safe replica-
tion-competent recombinant viruses such as avipoxviruses 
and ALVAC, which infect cells but do not replicate56,57. 
In another research on peptide-based vaccine, a JEV E 
protein was fused to Johnson grass mosaic virus coat pro-
tein by using recombinant DNA technology58. 
 Researchers have also constructed the Yellow fever  
virus to express JEV protein, the most promising recom-
binant vaccine under development. Widely known as 
ChimeriVax-JE, this vaccine incorporates the structural 
proteins (prM and E) of the JEV SA14-14-2 strain into 
YF17D, the yellow fever vaccine59–61.  
 Attempts have been made to generate DNA vaccines 
for JE and efficacy of various plasmid DNA constructs 
encoding the JEV E protein or prM has been evaluated in 
murine and primate models62–65. A single intramuscular 
injection of recombinant plasmid DNA containing cDNA 
encoding JEV prM and E proteins induced protective 
immunity and prevented JE in mice and their progeny63. 
Again, investigators have used both intramuscular injec-
tion and a gene gun to deliver the plasmid gene for E pro-
tein and prM protein64. DNA immunization with colloidal 
gold, construction of chimeric DNA vaccine vectors are 
the focus of some of the other recent promising stu-
dies65,66. A novel genetically engineered DNA vaccine 
against flavivirus has been proposed in which the consen-
sus sequence of structural domain III of the E protein of 
the virus that is reported to carry dominant epitopes that 
induce neutralizing antibodies, has been created. This has 
been administered along with a genetically engineered 
IL15 DNA vaccine molecular adjuvant for co-stimulating 
the immune response against DIII clones. This has  
resulted in a 4–5 fold increased immune response67. In 
another strategy, needle-free jet injection of a mixture of 
JEV DNA and protein vaccines was shown to enhance the 
immunogenicity of the DNA vaccine in a murine model68. 
Recently, pseudoinfectious JE viruses (named RepliVAX 
JE) lacking the JEV capsid protein capable of replicating 
in normal cells but incapable of producing infectious  
particles have been shown to protect mice and hamsters 
from lethal JEV challenge indicating that the RepliVAX 
platform can be used for producing a safe and potent JE 
vaccine69.  
Therapeutic measures against JE 
Chemotherapy against JE is at present supportive and not 
targeted at the virus. Interferon therapy has not met with 
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Table 1. Promising preventive and therapeutic strategies for Japanese encephalitis 
Prophylactic strategies – vaccine development 
 ChimeriVax-JE Incorporates the structural proteins (prM and E) of the JEV SA14-14-2 strain into YF17D,  
the Yellow fever vaccine 
 RepliVAX JE Pseudoinfectious JE viruses lacking the JEV capsid protein capable of replicating in normal 
cells but incapable of producing infectious particles 
 Vero cell-derived inactivated JE vaccine Contain purified, inactivated JEV strain SA14-14-2 with aluminum hydroxide as adjuvant;  
has passed phase III randomized control trials; Vero cell-derived vaccine based on an Indian 
strain of JEV has also been developed and is currently under pre-clinical development 
 Recombinant vaccinia and avipoxvirus JE vaccines using recombinant strains of vaccinia virus and avipoxvirus have been shown  
to be quite effective 
 Peptide-based vaccine JEV E protein was fused to Johnson grass mosaic virus coat protein by using recombinant 
DNA technology 
 DNA vaccines Efficacy of various plasmid DNA constructs encoding the JEV E protein or prM has been 
evaluated; DNA immunization with colloidal gold, construction of chimeric DNA vaccine 
vectors has also been found to be effective; the consensus sequence of structural domain III 
of the E protein of JEV that is reported to carry dominant epitopes that induce neutralizing 
antibodies, has been created an administered along with a genetically engineered IL15 DNA 
vaccine molecular adjuvant for co-stimulating the immune response against DIII clones 
 
Therapeutic strategies – drug development 
 Rosmarinic acid  Reduces JEV replication in mice brain and also ameliorates the secondary inflammation  
resulting from microglial activation 
 Arctigenin Confer substantial protection in a murine model from GP-78 strain of JEV infection by  
markedly decreasing virus-induced neuronal apoptosis, microglial activation, active  
caspase activity and induction of proinflammatory mediators in the brains 
 Curcumin Dysregulates ubiquitin-proteasome pathway to inhibit infective viral particle formation in  
in vitro studies; reduces JEV-induced cellular stress 
 N-methylisatin-β-thiosemicarbazone derivative Inhibits JEV replication 
 Glucosidase inhibitors Block the trimming step of N-linked glycosylation, thereby eliminate the production of  
several endoplasmic reticulum-budding viruses, including JEV 
 Minocycline Reduces neuronal apoptosis, microglial activation, active caspase activity, proinflammatory 
mediators and viral titer; possess antioxidative properties that significantly ameliorate  
the oxidative stress generated as a result of JEV infection; imparts protection to the  
blood–brain barrier that is severely compromised in JE 
 siRNA Single intracranial administration of lentivirus-delivered short hairpin RNA or  
lipid-complexed siRNA before viral challenge or siRNA treatment after viral challenge  
has been found to be sufficient to provide protection against lethal encephalitis 
 
 
great success70. Over-expression of interferon stimulating 
gene 15 has been found to impart protection against  
several viral infections71–74 and may also work against 
JEV. A recent clinical trial with oral administration of  
ribavarin, an antiviral drug that interferes with RNA meta-
bolism required for viral replication, was also not encour-
aging75. A naturally occurring compound discovered to 
have antiflaviviral activity and the potential to be deve-
loped as an antiflaviviral drug is rosmarinic acid (RA). 
RA, a phenolic compound found in various Labiatae 
herbs, possesses several anti-inflammatory and antioxida-
tive properties. An in-vivo study conducted with GP78 
strain of JEV in murine model has showed that RA re-
duces viral replication in mice brain and also ameliorates 
the secondary inflammation resulting from microglial  
activation76. Arctigenin, a naturally occurring phenylpro-
panoid dibenzylbutyrolactone lignan is known to possess 
antioxidant, anti-inflammatory, neuroprotective and anti-
viral properties. It has been reported that treatment with 
arctigenin confer substantial protection in a murine model 
from GP-78 strain of JEV infection by markedly decreas-
ing virus-induced neuronal apoptosis, microglial activation, 
active caspase activity and induction of proinflammatory 
mediators in the brains of arctigenin-treated mice77. The 
study also claims that arctigenin may act directly on brain 
cells, because neuronal cell line was also salvaged from 
JEV-induced cell death. Curcumin, a naturally occurring 
phenolic compound extracted from Curcuma longa L., 
has been shown to impart neuroprotection against JEV  
infection in an in-vitro study. Curcumin possibly acts by 
decreasing cellular reactive oxygen species level, restora-
tion of cellular membrane integrity, decreasing pro-apop-
totic signalling molecules, and modulating cellular levels 
of stress-related proteins. It has also been shown that the 
production of infective viral particles from previously  
infected neuroblastoma cells is reduced, which is achieved 
by the inhibition of ubiquitin-proteasome system78. 
 A remarkable achievement in anti-flaviviral drug res-
earch is the discovery of antiviral effect of minocycline, a 
member of the broad-spectrum antibiotic tetracycline 
group79. A significant piece of research on minocycline as 
an anti-JEV drug is an in-vivo study80 that showed mino-
cycline reduces neuronal apoptosis, microglial activation, 
active caspase factivity, proinflammatory mediators and 
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viral titer markedly on the 9th day post infection. Mino-
cycline was also shown to possess antioxidative proper-
ties that significantly ameliorate the oxidative stress 
generated as a result of JEV infection81. Minocycline also 
imparts protection to the BBB that is severely compro-
mised in JE22. Another compound that has shown inhi-
bition of JEV replication completely in vitro is an N-
methylisatin-β-thiosemicarbazone derivative82. 
 Glucosidase inhibitors of the endoplasmic reticulum, 
such as N-nonyl-deoxynojirimycin, which block the trim-
ming step of N-linked glycosylation, have been shown to 
eliminate the production of several endoplasmic reticu-
lum-budding viruses, including dengue type II (DEN-2) 
and JEV83. In a novel approach, a synthetic oligonucleo-
tide-based DNAzyme targeting the 3′NCR of JEV was 
shown to significantly inhibit virus replication in cultured 
cells and mouse brain and protected the JEV-infected 
mice from death66. In yet another innovative study on mice 
using RNA interference, a single intracranial administra-
tion of lentivirus-delivered short hairpin RNA or lipid-
complexed small interfering RNA (siRNA) before viral 
challenge or siRNA treatment after viral challenge was 
sufficient to provide protection against lethal encephali-
tis. Interestingly, when a cross-species conserved sequence 
of cd-loop coding viral envelope protein was targeted, 
encephalitis following both JEV and WNV challenge was 
avoided. This result clearly indicates that by careful drug 
design of the conserved target site, a single siRNA treat-
ment could suppress viral infection across species, 
thereby augmenting the treatment of acute viral infections 
with overlapping clinical symptoms84. 
Future perspectives 
With the advent of modern technologies and advance-
ment of knowledge, research in drug and vaccine deve-
lopment against JE has been going on at a steady rate for 
the past two decades. Though a lot of progress has been 
made in unraveling the mysteries of the virus that has 
helped in planning and designing countermeasure strate-
gies, the real success would be when an effective drug or 
vaccine would be easily available to the masses exposed 
to the threat of JE, at an affordable cost. Table 1 summa-
rizes the most promising prophylactic and therapeutic  
approaches against JE. It has been hypothesized that this 
virus may spread to greater geographic areas apart from 
its current endemic region. Thus it would be prudent to 
be prepared for epidemics of greater magnitudes.  
 
1. Solomon, T., Dung, N. M., Kneen, R., Gainsborough, M., Vaughn, 
D. W. and Khanh, V. T., Japanese encephalitis. J. Neurol. Neuro-
surg. Psychiatry., 2000, 68, 405–415. 
2. Gould, E. A., Evolution of the Japanese serological group viruses. 
In Current Topics in Microbiology and Immunology: Japanese  
Encephalitis and West Nile Virus Infections (eds Mackenzie, J. S., 
Barrett, A. D. and Deubel, V.), Springer-Verlag, Berlin, 2002, pp. 
391–404. 
3. Solomon, T., Ni, H., Beasley, D. W., Ekkelenkamp, M., Cardosa, 
M. J. and Barrett, A. D. T., Origin and evolution of Japanese  
encephalitis virus in southeast Asia. J. Virol., 2003, 77, 3091–
3098. 
4. Solomon, T., Control of Japanese encephalitis – within our grasp? 
N. Engl. J. Med., 2006, 355, 869–871. 
5. Tsai, T. F., New initiatives for the control of Japanese encephalitis 
by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thai-
land, 13–15 October 1998. Vaccine, 2000, 18, 1–25. 
6. Dhillon, G. P. and Raina, V. K., Epidemiology of Japanese  
encephalitis in context with Indian scenario. J. Indian. Med. 
Assoc., 2008, 106, 660–663.  
7. Kabilan, L., Rajendran, R., Arunachalam, N., Rameshm, S., Srini-
vasan, S., Samuel, P. P. and Dash, A. P., Japanese encephalitis in 
India: an overview. Indian J. Pediatr., 2004, 71, 609–615. 
8. Takahashi, M. and Suzuki, K., Japanese encephalitis virus in  
mosquito salivary glands. Am. J. Trop. Med. Hyg., 1979, 28, 122–
135. 
9. Zeidner, N. S., Higgs, S., Happ, C. M., Beaty, B. J. and Miller, B. 
R., Mosquito feeding modulates Th1 and Th2 cytokines in 
flavivirus susceptible mice: an effect mimicked by injection of  
sialokinins, but not demonstrated in flavivirus resistant mice. 
Parasite Immunol., 1999, 21, 35–44. 
10. Innis, B. L., Japanese encephalitis. In Exotic Viral Infections (ed. 
Porterfield, J. S.), Chapman and Hall, London, 1995, pp. 147–174. 
11. Solomon, T., Recent advances in Japanese encephalitis. J. Neuro-
virol., 2003, 9, 274–283. 
12. Ghosh, D. and Basu, A., Japanese encephalitis – a pathological 
and clinical perspective. PLoS Negl. Trop. Dis. (in press). 
13. Kaur, R. and Vrati, S., Development of a recombinant vaccine 
against Japanese encephalitis. J. Neurovirol., 2003, 9, 421–431. 
14. Kim, J.-M., Yun, S.-I., Song, B.-H., Hahn, Y.-S., Lee, C.-H., Oh, 
H.-W. and Lee, Y.-M., A single N-linked glycosylation site in the 
Japanese encephalitis virus prM protein is critical for cell type-
specific prM protein biogenesis, virus particle release, and patho-
genicity in mice. J. Virol., 2008, 82, 7846–7862. 
15. Ho, L.-J., Wang, J.-J., Shaio, M.-F., Kao, C.-L., Chang, D.-M., 
Han, S.-W. and Lai, J.-H., Infection of human dendritic cells by 
dengue virus causes cell maturation and cytokine production. J. 
Immunol., 2001, 166, 1499–1506. 
16. Johnston, L. J., Halliday, G. M. and King, N. J., Langerhans cells 
migrate to local lymph nodes following cutaneous infection with 
an arbovirus. J. Invest. Dermatol., 2000, 114, 560–568. 
17. Solomon, T. and Vaughn, D. W., Pathogenesis and clinical fea-
tures of Japanese encephalitis and West Nile virus infections. 
Curr. Top. Microbiol. Immunol., 2002, 267, 171–194. 
18. Diamond, M. S., Evasion of innate and adaptive immunity by 
flaviviruses. Immunol. Cell Biol., 2003, 81, 196–206. 
19. Yang, K. D. et al., A model to study neurotropism and persistency 
of Japanese encephalitis virus infection in human neuroblastoma 
cells and leukocytes. J. Gen. Virol., 2004, 85, 635–642. 
20. Aleyas, A. G. et al., Functional modulation of dendritic cells and 
macrophages by japanese encephalitis virus through MyD88 adap-
tor molecule-dependent and -independent pathways. J. Immunol., 
2009, 183, 2462–2474. 
21. Mathur, A., Khanna, N. and Chaturvedi, U. C., Breakdown of 
blood-brain barrier by virus-induced cytokine during Japanese  
encephalitis virus infection. Int. J. Exp. Pathol., 1992, 73, 603–
611. 
22. Mishra, M. K., Dutta, K., Saheb, S. K. and Basu, A., Understand-
ing the molecular mechanism of blood–brain barrier damage in an 
experimental model of Japanese encephalitis: correlation with  
minocycline administration as a therapeutic agent. Neurochem. 
Int., 2009 (in press). 
23. Ghoshal, A. et al., Proinflammatory mediators released by acti-
vated microglia induces neuronal death in Japanese encephalitis. 
Glia, 2007, 55, 483–496. 
SPECIAL SECTION: BIOLOGY AND PATHOGENESIS OF VIRUSES 
 
CURRENT SCIENCE, VOL. 98, NO. 3, 10 FEBRUARY 2010 333
24. Swarup, V., Ghosh, J., Das, S. and Basu, A., Tumor necrosis  
factor receptor-associated death domain mediated neuronal death 
contributes to the glial activation and subsequent neuroinflamma-
tion in Japanese encephalitis. Neurochem. Int., 2008, 52, 1310–
1321. 
25. Lin, Y. L. et al., Inhibition of Japanese encephalitis virus infection 
by nitric oxide: antiviral effect of nitric oxide on RNA virus repli-
cation. J. Virol., 1997, 71, 5227–5235. 
26. Chen, C. J., Liao, S. L., Kuo, M. D. and Wang, Y. M., Astrocytic 
alteration induced by Japanese encephalitis virus infection. Neu-
roreport, 2000, 11, 1933–1937. 
27. Kuhlow, C. J., Krady, J. K., Basu, A. and Levison, S. W., Astro-
cytic ceruloplasmin expression, which is induced by IL-1beta and 
by traumatic brain injury, increases in the absence of the IL-1 type 
1 receptor. Glia, 2003, 44, 76–84. 
28. Bhowmick, S., Duseja, R., Das, S., Appaiahgiri, M. B., Vrati, S. 
and Basu, A., Induction of IP-10 (CXCL10) in astrocytes follow-
ing Japanese encephalitis. Neurosci. Lett., 2007, 414, 45–50. 
29. Mishra, M. K., Koli, P., Bhowmick, S. and Basu, A., Neuroprotec-
tion conferred by astrocytes is insufficient to protect animals from 
succumbing to Japanese encephalitis. Neurochem. Int., 2007, 50, 
764–73. 
30. Saha, S. and Rangarajan, P, N., Common host genes are activated 
in mouse brain by Japanese encephalitis and rabies viruses. J. 
Gen. Virol., 2003, 84, 1729–1735. 
31. Saha, S., Sugumar, P., Bhandari, P. and Rangarajan, P. N., Identi-
fication of Japanese encephalitis virus inducible genes in mouse 
brain and characterization of GARG39/IFIT2 as a microtubule-
associated protein. J. Gen. Virol., 2006, 87, 3285–3289. 
32. Burke, D. S., Lorsomrudee, W., Leake, C. J., Hoke, C. H., 
Nisalak, A., Chongswasdi, V. and Laorakpongse, T., Fatal out-
come in Japanese encephalitis. Am. J. Trop. Med. Hyg., 1985, 34, 
203–1210. 
33. Vaughn, D. W. and Hoke, C. H., The epidemiology of Japanese 
encephalitis: prospects for prevention. Epidemiol. Rev., 1992, 14, 
197–221. 
34. Solomon, T. et al., Poliomyelitis-like illness due to Japanese  
encephalitis virus. Lancet, 1998, 351, 1094–1097. 
35. Kumar, S., Misra, U. K., Kalita, J., Sawani, V., Gupta, R. K. and 
Gujral, R., MRI in Japanese encephalitis. Am. J. Med. Sci., 1997, 
39, 180–184. 
36. Murgod, U. A., Muthane, U. B., Ravi, V., Radhesh, S. and Desai, 
A., Persistent movement disorders following Japanese encephali-
tis. Neurology, 2001, 57, 2313–2315. 
37. Liao, C. H. et al., Involvement of nigrostriatal pathway in Japa-
nese encephalitis with movement disorders: evidence from 
(99m)Tc-TRODAT-1 and (123)I-IBZM SPECT imagings. Mol. 
Imaging Biol., 2009 (in press). 
38. Kalita, J. and Misra, U. K., EEG in Japanese encephalitis: a 
clinico-radiological correlation. Electroencephalogr. Clin. Neuro-
physiol., 1998, 106, 238–243. 
39. Kumar, R., Mathur, A., Kumar, A., Sharma, S., Chakraborty, S. 
and Chaturvedi, U. C., Clinical features and prognostic indicators 
of Japanese encephalitis in children in Lucknow (India). Indian J. 
Med. Res., 1990, 91, 321–327. 
40. Ishii, T., Matsushita, M. and Hamada, S., Characteristic residual 
neuropathological features of Japanese B encephalitis. Acta. Neu-
ropathol., 1977, 38, 181–186. 
41. Das, S. and Basu, A., Japanese encephalitis virus infects neural 
progenitor cells and decreases their proliferation. J. Neurochem., 
2008, 106, 1624–1636. 
42. Sasaki, O., Karoji, Y., Kuroda, A., Karaki, T., Takenokuma, K. 
and Maeda, O., Protection of pigs against mosquito-borne Japa-
nese encephalitis virus by immunization with a live attenuated 
vaccine. Antiviral. Res., 1982, 2, 355–360. 
43. Solomon, T., New vaccines for Japanese encephalitis. Lancet  
Neurol., 2008, 7, 116–118. 
44. Shlim, D. R. and Solomon, T., Japanese encephalitis vaccine for 
travelers: exploring the limits of risk. Clin. Infect. Dis., 2002, 35, 
183–188. 
45. Okamoto, S. et al., Single dose of inactivated Japanese encephali-
tis vaccine with poly(gamma-glutamic acid) nanoparticles pro-
vides effective protection from Japanese encephalitis virus. 
Vaccine, 2008, 26, 589–594. 
46. Gowal, D. and Tahlan, A. K., Evaluation of effectiveness of 
mouse brain inactivated Japanese encephalitis vaccine produced in 
India. Indian J. Med. Res., 1995, 102, 267–271. 
47. http://www.expressindia.com/latest-news/Kasauli-CRIs-drug-licence- 
suspended/266285/ 
48. Jia, L., Wang, Z. and Yu, Y., Protection of SA14-14-2 live attenu-
ated Japanese encephalitis vaccine against the wild-type JE  
viruses. Chin. Med. J. (Engl.), 2003, 116, 941–943. 
49. Hennessy, S. et al., Effectiveness of live-attenuated Japanese  
encephalitis vaccine (SA14-14-2): a case-control study. Lancet, 
1996, 347, 1583–1586. 
50. http://www.who.int/vaccine_safety/topics/japanese_encephalitis/ 
live_attenuated/June_2005/en/index.html 
51. Tauber, E. et al., Safety and immunogenicity of a Vero- 
cell-derived, inactivated Japanese encephalitis vaccine: a non-
inferiority, phase III, randomised controlled trial. Lancet, 2007, 
370, 1847–1853. 
52. Appaiahgari, M. B. and Vrati, S., Immunogenicity and protective 
efficacy in mice of a formaldehyde-inactivated Indian strain of 
Japanese encephalitis virus grown in Vero cells. Vaccine, 2004, 
22, 3669–3675.  
53. Tartaglia, J. et al., NYVAC: a highly attenuated strain of vaccinia 
virus. Virology, 1992, 188, 217–232. 
54. Konishi, E., Pincus, S., Paoletti, E., Laegreid, W. W., Shope, R. E. 
and Mason, P. W., A highly attenuated host range-restricted vac-
cinia virus strain, NYVAC, encoding the prM, E, and NS1 genes 
of Japanese encephalitis virus prevents JEV viremia in swine.  
Virology, 1992, 190, 454–458. 
55. Nam, J. H., Wyatt, L. S., Chae, S. L., Cho, H. W., Park, Y. K. and 
Moss, B., Protection against lethal Japanese encephalitis virus  
infection of mice by immunization with the highly attenuated 
MVA strain of vaccinia virus expressing JEV prM and E genes. 
Vaccine, 1999, 17, 261–268. 
56. Konishi, E., Pincus, S., Paoletti, E., Shope, R. E. and Wason,  
P. W., Avipox virus-vectored Japanese encephalitis virus vac-
cines: use as vaccine candidates in combination with purified sub-
unit immunogens. Vaccine, 1994, 12, 633–638. 
57. Kanesa-thasan, N. et al., Safety and immunogenicity of attenuated 
dengue virus vaccines (Aventis Pasteur) in human volunteers. 
Vaccine, 2001, 19, 3179–3188. 
58. Saini, M. and Vrati, S., A Japanese encephalitis virus peptide  
present on Johnson grass mosaic virus-like particles induces virus-
neutralizing antibodies and protects mice against lethal challenge. 
J. Virol., 2003, 77, 3487–3494. 
59. Monath, T. P. et al., Recombinant, chimaeric live, attenuated  
vaccine (ChimeriVax) incorporating the envelope genes of Japa-
nese encephalitis (SA14-14-2) virus and the capsid and nonstruc-
tural genes of yellow fever (17D) virus is safe, immunogenic  
and protective in non-human primates. Vaccine, 1999, 17, 1869–
1882. 
60. Monath, T. P. et al., Chimeric yellow fever virus 17D-Japanese 
encephalitis virus vaccine: dose-response effectiveness and  
extended safety testing in rhesus monkeys. J. Virol., 2000, 74, 
1742–1751. 
61. Monath, T. P. et al., Clinical proof of principle for ChimeriVax: 
recombinant live, attenuated vaccines against flavivirus infections. 
Vaccine, 2002, 20, 1004–1018. 
62. Bharati, K., Rani, R. and Vrati, S., Evaluation of Japanese  
encephalitis virus DNA vaccine candidates in rhesus monkeys 
[Macaca mulatta]. Vaccine, 2009, 27, 10–16. 
SPECIAL SECTION: BIOLOGY AND PATHOGENESIS OF VIRUSES 
 
CURRENT SCIENCE, VOL. 98, NO. 3, 10 FEBRUARY 2010 334 
63. Chang, G. J., Hunt, A. R. and Davis, B., A single intramuscular  
injection of recombinant plasmid DNA induces protective immu-
nity and prevents Japanese encephalitis in mice. J. Virol., 2000, 
74, 4244–4252. 
64. Kaur, R., Sachdeva, G. and Vrati, S., Plasmid DNA immunization 
against Japanese encephalitis virus: immunogenicity of membrane-
anchored and secretory envelope protein. J. Infect. Dis., 2002, 
185, 1–12. 
65. Ashok, M. S. and Rangarajan, P. N., Protective efficacy of a plas-
mid DNA encoding Japanese encephalitis virus envelope protein 
fused to tissue plasminogen activator signal sequences: studies in 
a murine intracerebral virus challenge model. Vaccine, 2002, 20, 
1563–1570. 
66. Appaiahgari, M. B. and Vrati, S., DNAzyme-mediated inhibition 
of Japanese encephalitis virus replication in mouse brain. Mol. 
Ther., 2007, 15, 1593–1599. 
67. Ramanathan, M. P. et al., Coimmunization with an optimized IL15 
plasmid adjuvant enhances humoral immunity via stimulating  
B cells induced by genetically engineered DNA vaccines express-
ing consensus JEV and WNV E DIII. Vaccine, 2009, 27, 4370–
4380. 
68. Imoto, J. and Konishi, E., Needle-free jet injection of a mixture of 
Japanese encephalitis DNA and protein vaccines: a strategy to  
effectively enhance immunogenicity of the DNA vaccine in a mur-
ine model. Viral Immunol., 2005, 18, 205–212. 
69. Ishikawa, T., Widman, D. G., Bourne, N., Konishi, E. and Mason, 
P. W., Construction and evaluation of a chimeric pseudoinfectious 
virus vaccine to prevent Japanese encephalitis. Vaccine, 2008, 26, 
2772–2781. 
70. Solomon, T. et al., Interferon alfa-2a in Japanese encephalitis: a 
randomised double-blind placebo-controlled trial. Lancet, 2003, 
361, 821–826. 
71. Zhao, C., Denison, C., Huibregtse, J. M., Gygi, S. and Krug, R. 
M., Human ISG15 conjugation targets both IFN-induced and con-
stitutively expressed proteins functioning in diverse cellular path-
ways. Proc. Natl. Acad. Sci. USA, 2005, 102, 10200–10205. 
72. Yuan, W. and Krug, R. M., Influenza B virus NS1 protein inhibits 
conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 
protein. EMBO J., 2001, 20, 362–371. 
73. Loo, Y. M. et al., Viral and therapeutic control of IFN-beta pro-
moter stimulator 1 during hepatitis C virus infection. Proc. Natl. 
Acad. Sci. USA, 2006, 103, 6001–6006. 
74. Okumura, A., Lu, G., Pitha-Rowe, I. and Pitha, P. M., Innate anti-
viral response targets HIV-1 release by the induction of ubiquitin-
like protein ISG15. Proc. Natl. Acad. Sci. USA, 2006, 103, 1440–
1445. 
75. Kumar, R., Tripathi, P., Baranwal, M., Singh, S., Tripathi, S. and 
Banerjee, G., Randomized, controlled trial of oral ribavirin  
for Japanese encephalitis in children in Uttar Pradesh, India. Clin.  
Infect. Dis., 2009, 48, 400–406. 
76. Swarup, V., Ghosh, J., Ghosh, S., Saxena, A. and Basu, A., Anti-
viral and anti-inflammatory effects of rosmarinic acid in an  
experimental murine model of Japanese encephalitis. Antimicrob. 
Agents Chemother., 2007, 51, 3367–3370. 
77. Swarup, V., Ghosh, J., Mishra, M. K. and Basu, A., Novel strategy 
for treatment of Japanese encephalitis using arctigenin, a plant 
lignan. J. Antimicrob. Chemother., 2008, 61, 679–688. 
78. Dutta, K., Ghosh, D. and Basu, A., Curcumin protects neuronal 
cells from Japanese encephalitis virus-mediated cell death and also 
inhibits infective viral particle formation by dysregulation of ubi-
quitin-proteasome system. J. Neuroimmune. Pharmacol., 2009, 4, 
328–337.  
79. Michaelis, M., Kleinschmidt, M. C., Doerr, H. W. and Cinatl Jr, J., 
Minocycline inhibits West Nile virus replication and apoptosis in 
human neuronal cells. J. Antimicrob. Chemother., 2007, 60, 981–
986. 
80. Mishra, M. K. and Basu, A., Minocycline neuroprotects, reduces 
microglial activation, inhibits caspase 3 induction, and viral repli-
cation following Japanese encephalitis. J. Neurochem., 2008, 105, 
1582–1595. 
81. Mishra, M. K., Ghosh, D., Duseja, R. and Basu, A., Antioxidant 
potential of Minocycline in Japanese encephalitis virus infection 
in murine neuroblastoma cells: correlation with membrane fluidity 
and cell death. Neurochem. Int., 2009, 54, 464–470. 
82. Sebastian, L., Desai, A., Shampur, M. N., Perumal, Y., Sriram, D., 
Vasanthapuram, R., N-methylisatin-beta-thiosemicarbazone deri-
vative (SCH 16) is an inhibitor of Japanese encephalitis virus  
infection in vitro and in vivo. J. Virol., 2008, 5, 64–75. 
83. Wu, S. F., Lee, C. J., Liao, C. L., Dwek, R. A., Zitzmann, N. and 
Lin, Y. L., Antiviral effects of an iminosugar derivative on 
flavivirus infections. J. Virol., 2002, 76, 3596–3604. 
84. Kumar, P., Lee, S. K., Shankar, P. and Manjunath, N., A single 
siRNA suppresses fatal encephalitis induced by two different 
flaviviruses. PLoS Med., 2006, 3, e96. 
 
 
 
 
 
 
